Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods.

This study compares the physicochemical properties of carbamazepine (CBZ) solid dispersions prepared by either a conventional solvent evaporation versus a supercritical fluid process. Solid dispersions of carbamazepine in polyvinylpyrrolidone (PVP) K30 with either Gelucire 44/14 or Vitamin E TPGS, NF (d-alpha-tocopheryl polyethylene glycol 1000 succinate) were prepared and characterized by intrinsic dissolution, differential scanning calorimetry, powder X-ray diffraction and Fourier transform infrared spectroscopy. CBZ/PVP K30 and CBZ/PVP K30/TPGS solid dispersions showed increased dissolution rate. The best intrinsic dissolution rate (IDR) was obtained for supercritically processed CBZ/PVP K30 that was four-fold higher than pure CBZ. Thermograms of various solid dispersions did not show the melting peak of CBZ, indicating that CBZ was in amorphous form inside the carrier system. This was further confirmed by X-ray diffraction studies. Infrared spectroscopic studies showed interaction between CBZ and PVP K30 in solid dispersions. The amorphous state of CBZ coupled with presence of interaction between drug and PVP K30 suggests fewer, if any, stability problems. Because the supercritical-based process produced solid dispersions with IDR better than conventional solid dispersions augmented with amphiphilic carriers, stability issues associated with lipid carriers do not apply, which, in turn, implies easier scale up under current Good Manufacturing Practice for this technique.

[1]  C. Porter,et al.  The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: physical stability and absolute bioavailability assessment. , 2000, International journal of pharmaceutics.

[2]  M. Gibaldi,et al.  New method of solid-state dispersion for increasing dissolution rates. , 1966, Journal of pharmaceutical sciences.

[3]  D. Brooke,et al.  Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis. , 1991, Journal of pharmaceutical sciences.

[4]  Lynne S. Taylor,et al.  Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions , 1997, Pharmaceutical Research.

[5]  Emilio Squillante,et al.  Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. , 2002, Journal of pharmaceutical sciences.

[6]  R. Löbenberg,et al.  Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  T. Nagai,et al.  Studies on powdered preparation. XVII. Dissolution rate of sulfonamides by rotating disk method. , 1966, Chemical and pharmaceutical bulletin.

[8]  L. Bertilsson Clinical Pharmacokinetics of Carbamazepine , 1978, Clinical pharmacokinetics.

[9]  S. Hoag,et al.  Influence of various drugs on the glass transition temperature of poly(vinylpyrrolidone): a thermodynamic and spectroscopic investigation. , 2001, International journal of pharmaceutics.

[10]  Ford Jl,et al.  The current status of solid dispersions. , 1986 .

[11]  F. Krahn,et al.  Relations between several polymorphic forms and the dihydrate of carbamazepine. , 1987, Pharmaceutica acta Helvetiae.

[12]  P. York,et al.  Control of the Physical Form of Salmeterol Xinafoate , 1999 .

[13]  York,et al.  Strategies for particle design using supercritical fluid technologies. , 1999, Pharmaceutical science & technology today.

[14]  B. Perissutti,et al.  Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation, and in vitro dissolution. , 2001, International journal of pharmaceutics.

[15]  George Zografi,et al.  Physical Properties of Solid Molecular Dispersions of Indomethacin with Poly(vinylpyrrolidone) and Poly(vinylpyrrolidone-co-vinyl-acetate) in Relation to Indomethacin Crystallization , 1999, Pharmaceutical Research.

[16]  J Dressman,et al.  Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  A. Serajuddin,et al.  Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. , 1999, Journal of pharmaceutical sciences.

[18]  C. Rustichelli,et al.  Solid-state study of polymorphic drugs: carbamazepine. , 2000, Journal of pharmaceutical and biomedical analysis.

[19]  Patrick Augustijns,et al.  Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30 , 1998 .

[20]  A. P. Lötter,et al.  Physicochemical properties and X-ray structural studies of the trigonal polymorph of carbamazepine. , 1987, Journal of pharmaceutical sciences.

[21]  R. Silverstein,et al.  Spectrometric identification of organic compounds , 2013 .

[22]  V. Krukonis,et al.  Gas Antisolvent Recrystallization: New Process To Recrystallize Compounds Insoluble in Supercritical Fluids , 1989 .

[23]  Stanley A. Kaplan,et al.  Biopharmaceutical Considerations in Drug Formulation Design and Evaluation , 1972 .

[24]  P Augustijns,et al.  Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[25]  Emilio Squillante,et al.  Solid dispersions: revival with greater possibilities and applications in oral drug delivery. , 2003, Critical reviews in therapeutic drug carrier systems.

[26]  T. Higuchi,et al.  Phase solubility techniques , 1965 .